IPO Price Range: ₹1265 - 1329
Min Investment
₹14,619
IPO Size
₹2,497 Cr
IPO Status
Live
Quantity in 1 Lot
11
Max Bid allowed
13
Listing Exchange
NSE
Bid Opening Date | 12 Dec 2024 |
Bid Closing Date | 16 Dec 2024 |
Allotment Date | 17 Dec 2024 |
Issue Size | ₹2,497.92Cr |
Quantity in 1 lot | 11 |
Comprehensive one-stop platform with diversified offerings across the outpatient and inpatient carevalue chain serving key stakeholders such as patients, physicians, nurses and healthcare organizations.
Leveraging digital evolution, transformation and automation technologies to create sustained valuebased on outcomes delivered.
Strong brand driven by clinical thought leadership through IKS Advisory Board, a healthcare industryleadership forum, and partnerships with industry players and evident through multiple awards andrecognitions.
Marquee large enterprise clientele that include academic medical centres and healthcare systems, multispecialty and single-specialty medical groups, ancillary healthcare organizations, value enablers, and other outpatient healthcare delivery organizations and client stickiness reflected in revenues from repeat clients of over 98% in the last three Fiscals.
Sustainable and scalable business model offering clients flexibility and cost-savings and high-touch engagement through access to project executive sponsors and leadership teams creating cross-selling opportunities.
Healthy financial performance with growth and improving margins.
Experienced and entrepreneurial driven leadership team.
There have been certain FEMA related deficiencies in compliances in the past by the Company andsome of its existing and erstwhile shareholders, with respect to issuance of securities of the Company, delays in relation to reporting requirements and transfer of securities of the Company. The company has filed compounding applications with the RBI in respect of such contraventions, which are currently pending. Consequently, its may be subject to regulatory actions and penalties/ compounding fees, as applicable.
The company has outstanding litigation against it, an adverse outcome of which may adversely affect its business, reputation and results of operations.
If the company fails to successfully develop and introduce new solutions based on artificial intelligence and machine learning technologies and features to existing solutions such as AI-powered speech-to-text solutions, its revenues, operating results and reputation could suffer.
The healthcare industry is regulated and if the company fails to comply with applicable healthcare laws and government regulations, its could incur financial penalties, be required to make significant operational changes or experience adverse publicity, which could harm its business.
Various challenges currently faced by the healthcare industry in the United States including the provision of quality healthcare in a competitive environment and managing costs at the same time and consolidation of healthcare organizations in the United States may adversely affect its business, results of operations and financial condition.
The company revenues are dependent on its ability to maintain and expand existing client relationships and its ability to attract new clients. As of September 30, 2024 and 2023 and as of March 31, 2024, 2023 and 2022, the company had 778, 42, 853, 49 and 45 clients. A loss of one or more clients could have an adverse impact on its results of operations, financial condition and cash flows.
The company has recently acquired Aquity Holdings to further its strategic objectives. The company inability to successfully integrate the operations of Aquity or the operations of any entities that its may acquires could adversely impact its business, financial condition, results of operations, cash flows and prospects.
The Company will not receive any proceeds from the Offer. Some of its Shareholders are sellingshares in the Offer and will receive proceeds as part of the Offer for Sale.
Delays in receiving payment of outstanding dues from clients may affect its financial condition and results of operations.
Its revenues are primarily dependent on revenue generated from healthcare organizations based inthe United States, and as a result, the company is subject to the risks of sector and geographic concentration.
Investors | Holdings % |
Sachin Gupta | 10.23% |
Rekha Jhunjhunwala | 0.23% |
Aryamann Jhujhunwala Discretio | 17.37% |
Aryavir Jhunjhuwala Discretion | 17.37% |
Nishtha Jhunjhuwala Discreatio | 17.37% |
Organisation | Inventurus Knowledge Solutions Ltd |
Headquarters | Airoli |
Industry | IT - Software |